Business Context and Reporting Period
This Form 8-K Current Report is filed by Athira Pharma, Inc. (trading symbol: ATHA) on October 16, 2024. The registrant is a Delaware corporation headquartered in Bothell, Washington, and its common stock is listed on The Nasdaq Global Select Market. The report addresses regulatory compliance issues regarding stock price and upcoming capital market activities.
Key Financial Metrics
This filing is a current report regarding corporate events and does not contain financial statements. Consequently, specific values for revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Events
- Nasdaq Non-Compliance Notice: On October 16, 2024, the Company received a notice from Nasdaq stating it failed to meet the minimum bid price requirement of $1.00 per share for 30 consecutive business days.
- Compliance Timeline: The Company has an initial 180-day compliance period ending April 14, 2025, to regain compliance. This requires the closing bid price to be at least $1.00 for 10 consecutive business days.
- Delisting Risk: Failure to regain compliance by April 14, 2025, may result in delisting unless the Company qualifies for a second 180-day period by transferring to the Nasdaq Capital Market, potentially via a reverse stock split.
- Registration Statement: The Company intends to file a new Form S-3 registration statement to replace its expiring 2021 statement (expiring November 24, 2024). The new statement would allow the offering of up to $300,000,000 in securities.
Guidance, Outlook, and Risks
Management intends to actively monitor the stock price and consider all options to regain compliance, including seeking stockholder approval for a reverse stock split. However, the Company explicitly states there is no assurance it will regain compliance within the initial or potential second compliance periods.
Key Risks Identified:
- Failure to meet the $1.00 minimum bid price requirement.
- Potential delisting from Nasdaq if compliance is not achieved.
- Uncertainty regarding the effectiveness of the new Form S-3 registration statement.
- General risks associated with accessing public capital markets.
Investor Verification Checklist
- Verify the current closing bid price of ATHA stock to assess the severity of the deficiency.
- Monitor for any shareholder meeting notices regarding a potential reverse stock split.
- Confirm the filing and effectiveness of the new Form S-3 registration statement.
- Review the Company's most recent 10-K or 10-Q for actual financial health metrics (cash runway, debt levels) not included in this 8-K.
- Track the April 14, 2025, deadline for the initial compliance period.